TRIAL DETAIL

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Drug:
Trial Name:
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
NCT#:
Conditions:
Solid Tumors
Status:
Active, not recruiting
Phase:
1/2
Start Date 04/01/2015
Age of Trial (yrs) 6.7
Treatment Phase:
Gleevec-resistant
Drug Category:
PD-1 Inhibitor
Strategy:
Stimulate the immune system
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
CPDR001X2101, 2014-003929-17
Sponsor:
Novartis
Patient Contact:
Novartis Pharmaceuticals 1-888-669-6682 +41613241111
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:

Trial Links

Trial Results

Drug Information

Novartis R&D page
 

Trial Sites

Name
Address
City
State
Zip
Country
Baltimore
MD
21231
USA
55 Fruit Street
Boston
MA
02114
USA
Portland
OR
97239
USA
3322 West End Avenue
Nashville
TN
37203
USA
1505 Holcombe Blvd.
Houston
TX
77030
USA
2000 Circle of Hope
Salt Lake City
UT
84103
USA
Toronto
ON
Canada
Villejuif
Val de Narne
94805
France
Amsterdam
Netherlands
Leiden
2300 RC
Netherlands
119-129
Barcelona
08035
Spain
Taipei
Taiwan
Toulouse
31052
France
Madrid
28050
Spain
Tainan City
Taiwan
Paris
France
Ulm
89081
Germany
Oslo
N-0310
Norway
Milan
20132
Italy
Napoli
80131
Italy